Is Septerna, Inc. (SEPN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.0% / 30% | 27.2% / 30% | 0.1% / 30% | 801.58% / 5% | ✗ NOT HALAL |
| DJIM | 2.0% / 33% | 27.2% / 33% | 0.1% / 33% | 801.58% / 5% | ✗ NOT HALAL |
| MSCI | 5.6% / 33% | 76.9% / 33% | 0.2% / 33% | 801.58% / 5% | ✗ NOT HALAL |
| S&P | 2.0% / 33% | 27.2% / 33% | 0.1% / 33% | 801.58% / 5% | ✗ NOT HALAL |
| FTSE | 5.6% / 33% | 76.9% / 33% | 0.2% / 50% | 801.58% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -66.4% | |
| Net Margin | -106.4% | |
| Return on Equity (ROE) | -12.2% | |
| Return on Assets (ROA) | -9.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $110M |
| Free Cash Flow | $110M |
| Total Debt | $24M |
| Debt-to-Equity | 6.2 |
| Current Ratio | 4.7 |
| Total Assets | $596M |
Price & Trading
| Last Close | $24.74 |
| 50-Day MA | $26.41 |
| 200-Day MA | $20.31 |
| Avg Volume | 298K |
|
52-Week Range
$4.66
| |
About Septerna, Inc. (SEPN)
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Septerna, Inc. (SEPN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Septerna, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Septerna, Inc.'s debt ratio?
Septerna, Inc.'s debt ratio is 2.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.6%.
What are Septerna, Inc.'s key financial metrics?
Septerna, Inc. has a market capitalization of $1.1B, and revenue of $46M. The company maintains a gross margin of 100.0% and a net margin of -106.4%. Return on equity stands at -12.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.